Personalized T-Cell Polypeptide Vaccination

Compositions and methods of synthetic polypeptides for the generation of therapeutic and prophylactic vaccines.

  • Stage: Preclinical in vitro
  • Type: Therapeutic, Vaccine
  • Categories: Immuno Oncology, Protein / Peptide

Technology Overview

For therapeutic vaccination or cure efforts, T-cell mediated cellular immunity is critical. In order to mount an effective T-cell response, the foreign (exogenous) antigen must be recognized by the immune system and presented to T-cells. Fred Hutch researchers have elucidated the critical role of the HLA-F and MHC-1 open conformer processing pathway in recognizing cancer and viral antigens. By understanding a patient’s HLA fingerprint, personalized peptide vectors can be generated to elicit a potent T-cell mediated adaptive immune response to kill target cells.


  • Compositions and methods for personalized T-cell vaccines for cancer and infectious disease indications


  • Platform can be manipulated and personalized in vitro at low cost
  • Platform can be applied to cancer, viral, and tumor neoantigens
  • Peptide vaccines are easy to handle, store, and transport
  • Lower cost of goods as compared to subunit or whole protein vaccines

Patent Information

WO 2014160902

Market Overview

The global vaccine market overall is predicted to double to approximately $58 billion by 2016 due to an increased prevalence of disease, increases in government sponsored programs and application of novel technologies. The global market for cancer vaccines was $4.5 billion in 2013 with a CAGR of 1.3% for the period of 2014-2019.

Investigator Overview

Daniel Geraghty, PhD, Clinical Research Division
Tech ID: 13-031
Asset 1